Go back to News
NEWS
GA_P advises Uriach on the sale of its generics and b2b business to MCH
Gómez-Acebo & Pombo has advised Grupo J. Uriach on the sale of its B2B business to the investment fund MCH, with the participation of a group of investors. With this transaction, Uriach completes the process of divestment in the pharmaceutical sector and sale of generics, to focus on its strategic business plan in the Consumer Healthcare (CHC) sector.
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
Lawyer mentioned
Daniel Marín – Partner
Carolina Posse Van Der Laat – Senior associate
See all lawyers
See less lawyers
Category
Deal
Press contact

Sandra Cuesta
Director of Business Development, Marketing and Communications

Sandra Cuesta
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
PUBLICATION
2 days ago
Absolute prohibitions on pharmacy advertising are contrary to EU law
In its judgment of 19 June 2025 (European Commission v Republic of Poland, C‑200/24, ECLI:EU:C:2025:459), the Court of Justice has held that the introduction by national legislation of a total prohibition on advertising for pharmacies infringes European Union law.
PUBLICATION
09 Jul, 2025
Once again on the obligations assumed by the signers of a "strong" comfort letter
PUBLICATION
02 Jul, 2025
Pharma & Healthcare No. 44
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
19 Jun, 2025
Company resolutions reached with invalid votes
Although Article 204(3)(d) places them on the same level, the erroneous counting of votes and the counting of invalid votes are very different, given that the latter requires judicial balancing.
PUBLICATION
12 May, 2025
Automotive and Sustainable Mobility No. 26
Summary of legislative and case law developments in the automotive sector.
PUBLICATION
16 Apr, 2025
Pharma & Healthcare No. 43
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
PUBLICATION
27 Mar, 2025
The notion of ‘pharmacological action’ in the legal concept of medicinal product
A look at the judgment of the Court of Justice in Case C-589/23, Cassella-med and MCM Klosterfrau, ECLI:EU:C:2025:173.
PUBLICATION
25 Mar, 2025
A first ranking mortgage does not prevent a creditor from accelerating loan maturity due to debtor insolvency
If the creditor has a secured claim (even if the debt is covered by the "value of the security", i.e. the claim is in the money), the debtor cannot avoid the effects of the to-term forfeiture by appealing to the existence of that security because the guarantee referred to in Article 1129(1) of the Civil Code (avoiding to-term forfeiture) must then be another additional guarantee.
PUBLICATION
25 Mar, 2025
La existencia de una hipoteca de primer rango no impide que el acreedor pueda declarar el vencimiento anticipado del plazo por insolvencia sobrevenida del deudor
Si el acreedor goza de una garantía real para la seguridad de su crédito (incluso si la deuda está cubierta por el «valor de la garantía», es decir, que el crédito está in the money), el deudor no puede evitar los efectos de la pérdida del plazo apelando a la existencia de aquella garantía real porque la garantía a que se refiere el artículo 1129.1.º del Código Civil (evitadora de la pérdida del plazo) deberá ser entonces otra garantía suplementaria.